Merck will return the global marketing and development rights for intravenous (IV) and oral formulations for vernakalant to Cardiome Pharma. The company referred to the move as “a business decision.”   Vernakalant IV is marketed under the brand name Brinavess and is approved in the EU for recent onset atrial fibrillation (AF) to sinus rhythm in adults. Vernakalant IV is not approved for use in the U.S. or Canada. The companies will work together to transition activities and ensure continued avai...